Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay005 in liver impairment
NCT06376474Phase 1Recruiting
- Sponsor
- Hemay Pharmaceutical Technology
- Start
- Apr 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mufemilast in psoriasis (3 arms), sponsored by Hemay Pharmaceutical Technology. Primary endpoints: Peak Plasma Concentration, Area Under the Plasma Concentration Versus Time Curve and 4 more. Started Apr 2024; status: recruiting.
02
Drugs
mufemilast
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06376474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06376474.